CORVUS PHARMACEUTICALS INC. - COMMON STOCK

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

01 Nov 2023 19:31:53 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

31 Oct 2023 16:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

08 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

01 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

06 Jul 2023 12:59:15 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

15 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

31 May 2023 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

17 May 2023 09:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

08 May 2023 16:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

20 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

17 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

03 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

28 Mar 2023 16:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

21 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

14 Mar 2023 16:35:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

12 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

05 Dec 2022 08:30:00 By Nasdaq GlobeNewswire